1. SST001 Pollak M.N. and Schally A.V. (1998) Mechanisms of Antineoplastic Action of somatostatin Analogs. Proc Soc Exp Biol Med. 217(2):143-152. (link)
2. SST002 S. Pyronnet et al. (2008) Antitumor effects of somatostatin. Molecular and Cellular Endocrinology 286 (2008) 230–237. (link)
3. SST003 Pai et al (2015) Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacology & Therapeutics 152: 98-110. (link)
4. SST004 Cascinu et al. (2014) Inhibition of Vascular Endothelial Growth Factor by Octreotide in Colorectal Cancer Patients. Cancer Investigation 19(1), 8–12. (link)
5. SST005 Danesi et al. (1997) Inhibition of Experimental Angiogenesis by the Somatostatin Analogue Octreotide Acetate (SMS 2O1-995). Clinical Cancer Research 3(2):265-72. (link)
6. SST006 Reubi and Laissue (1995) Multiple actions of somatostatin in neoplastic disease. Trends in Pharmacological Sciences 16 (3): 110-115. (link)
7. SST007 Schally A.V. (1998) Oncological Applications of Somatostatin Analogues. Cancer Research 48, 6977-6985. (link)
8. SST008 Schally A.V. et al. (1990) Antitumor effects of analogs of LHRH and somatostatin: experimental anche clinical studies. Journal of Steroid Biochemistry and Molecular Biology 37 (6): 1061-1067 (link)
9. SST009 G-Garcia et al. (2025) Valutazione del potenziale diagnostico, prognostico e terapeutico del sistema somatostatina/cortistatina nel glioblastoma - Assessing the diagnostic, prognostic, and therapeutic potential of the somatostatin/cortistatin system in glioblastoma. Cellular and Molecular Life Sciences 82, 173. (link)
10. SST10 Sanjuan-Sanjuan et al. (2021) "Implicazioni molecolari e cliniche del profilo dei recettori della somatostatina e del trattamento con analoghi della somatostatina nel carcinoma a cellule squamose del cavo orale " Cancers 2021, 13(19), 4828. (LINK)
11. SST011 Sáez-Martínez et al. 2022 “Somatostatina, cortistatina e i loro recettori esercitano azioni antitumorali nelle cellule del cancro alla prostata androgeno-indipendente: ruolo cruciale della cortistatina endogena – Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin” International Journal of Molecular Sciences 23(21):13003 (LINK)
12. SST012 Leiszter et al. 2015 “La ridotta produzione di somatostatina correlata all’ipermetilazione del promotore favorisce la proliferazione cellulare incontrollata nel cancro del colon-retto – Promoter Hypermethylation-Related Reduced Somatostatin Production Promotes Uncontrolled Cell Proliferation in Colorectal Cancer”. PLoS ONE 10(2): e0118332 (link)
13. SST013 Yamamoto et al. 2014 “Regolazione degli effetti citostatici mediati dal recettore 4 della somatostatina da parte di CD26 nel mesotelioma pleurico maligno - Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma” British Journal of Cancer 110, 2232–2245 (2014)
14. SST014 Oron-Herman et al. 2023 “Prevalenza e dinamiche di espressione dei recettori GPCR della somatostatina 2 e 3 come biomarcatori tumorali oltre i tumori neuroendocrini: un approccio mediante immunoistochimica accoppiata – Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach” Scientific Report 13, 20857

Recettori della somatostatina (SSTr)

1.  SSTr001 Zou Y., et al. (2019) Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. Oncology Letters 17: 1723-1731 (link)
2. SSTr002 Priyadarshini et al. (2022) “Valutazione completa dei recettori della somatostatina in varie neoplasie: una revisione sistematica – Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review.” Pharmaceutics, 14(7), 1394 (link)